Large-scale production of red blood cells from stem cells: What are the technical challenges ahead?

2013 ◽  
Vol 9 (1) ◽  
pp. 28-38 ◽  
Author(s):  
Guillaume F. Rousseau ◽  
Marie-Catherine Giarratana ◽  
Luc Douay
Keyword(s):  
Stem Cells ◽  
Red Blood Cells ◽  
Blood Cells ◽  
Large Scale ◽  
Scale Production ◽  
Large Scale Production ◽  
Technical Challenges

Large-scale production of embryonic red blood cells from human embryonic stem cells

2006 ◽  
Vol 34 (12) ◽  
pp. 1635-1642 ◽  
Author(s):  
Emmanuel N. Olivier ◽  
Caihong Qiu ◽  
Michelle Velho ◽  
Rhoda Elison Hirsch ◽  
Eric E. Bouhassira
Keyword(s):  
Stem Cells ◽  
Embryonic Stem Cells ◽  
Red Blood Cells ◽  
Human Embryonic Stem Cells ◽  
Blood Cells ◽  
Large Scale ◽  
Embryonic Stem ◽  
Scale Production ◽  
Large Scale Production

scholarly journals Iron-loaded deferiprone can support full hemoglobinization of cultured red blood cells in the absence of transferrin

2021 ◽  
Author(s):  
Joan Sebastián Gallego-Murillo ◽  
Nurcan Yağcı ◽  
Eduardo Machado Pinho ◽  
Adrián Abeijón-Valle ◽  
Aljoscha Wahl ◽  
...  
Keyword(s):  
Red Blood Cells ◽  
Cell Lines ◽  
Blood Cells ◽  
Large Scale ◽  
Myeloid Cell ◽  
Scale Production ◽  
Hematopoietic Stem ◽  
Cell Therapies ◽  
Large Scale Production

Iron is an essential nutrient in mammalian cell cultures, conventionally supplemented as iron-loaded transferrin (holotransferrin). The high cost of human transferrin represents a challenge for the large scale production of cell therapies, such as cultured red blood cells. We evaluated the use of deferiprone, a cell membrane-permeable drug for iron chelation therapy, as an iron carrier for erythroid cultures. Iron-loaded deferiprone (Def3·Fe3+) at a concentration of 52μmol/L could fully replace holotransferrin during erythroblast differentiation into reticulocytes, the erythroid differentiation stage with maximal iron requirements. Reticulocytes cultured in presence of Def3·Fe3+ or holotransferrin (1000μg/mL) were similar with respect to expression of cell-surface markers CD235a and CD49d, hemoglobin content, and oxygen association/dissociation. Def3·Fe3+ also supported expansion of the erythroid compartment in vitro, except for the first stage when hematopoietic stem cells committed to erythroblasts, in which a reduced erythroblasts yield was observed. This suggests that erythroblasts acquired the potential to process Def3·Fe3+ as iron source for biosynthesis pathways. Replacement of holotransferrin by Def3·Fe3+ was also successful in cultures of six myeloid cell lines (MOLM13, NB4, EOL1, K562, HL60, ML2). These results suggest that iron-loaded deferiprone can partially replace holotransferrin in chemically defined medium formulations for the production of cultured reticulocytes and proliferation of selected myeloid cell lines. This would lead to a significant decrease in medium cost that would improve the economic perspectives of the large scale production of red blood cells for transfusion purposes.

scholarly journals Large‐Scale Production of LGR5‐Positive Bipotential Human Liver Stem Cells

Hepatology ◽  
2020 ◽  
Vol 72 (1) ◽  
pp. 257-270 ◽  
Author(s):  
Kerstin Schneeberger ◽  
Natalia Sánchez‐Romero ◽  
Shicheng Ye ◽  
Frank G. Steenbeek ◽  
Loes A. Oosterhoff ◽  
...  
Keyword(s):  
Stem Cells ◽  
Human Liver ◽  
Large Scale ◽  
Scale Production ◽  
Liver Stem Cells ◽  
Large Scale Production

Large-Scale Production of Human Adipose Tissue from Stem Cells: A New Tool for Regenerative Medicine and Tissue Banking

2008 ◽  
pp. 110306231138043
Author(s):  
Francesco D'andrea ◽  
Francesco De Francesco ◽  
Giuseppe A. Ferraro ◽  
Vincenzo Desiderio ◽  
Virginia Tirino ◽  
...  
Keyword(s):  
Stem Cells ◽  
Adipose Tissue ◽  
Regenerative Medicine ◽  
Large Scale ◽  
Tissue Banking ◽  
Human Adipose Tissue ◽  
Scale Production ◽  
Large Scale Production

Large-scale production of human mesenchymal stem cells for clinical applications

2012 ◽  
Vol 59 (2) ◽  
pp. 106-120 ◽  
Author(s):  
Sunghoon Jung ◽  
Krishna M. Panchalingam ◽  
Reynold D. Wuerth ◽  
Lawrence Rosenberg ◽  
Leo A. Behie
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Large Scale ◽  
Human Mesenchymal Stem Cells ◽  
Clinical Applications ◽  
Scale Production ◽  
Large Scale Production

scholarly journals In vitro characterization of engineered red blood cells as potent viral traps against HIV-1 and SARS-CoV-2

2020 ◽  
Author(s):  
Magnus A. G. Hoffmann ◽  
Collin Kieffer ◽  
Pamela J. Bjorkman
Keyword(s):  
Red Blood Cells ◽  
Blood Cells ◽  
Large Scale ◽  
Viral Infections ◽  
Expression System ◽  
Scale Production ◽  
Specific Expression ◽  
In Vitro Characterization ◽  
Hiv 1

AbstractEngineered red blood cells (RBCs) expressing viral receptors could be used therapeutically as viral traps as RBCs lack nuclei and other organelles required for viral replication. Here we show that the combination of a powerful erythroid-specific expression system and transgene codon optimization yields high expression levels of the HIV-1 receptors CD4 and CCR5, as well as a CD4-glycophorin A (CD4-GpA) fusion protein on enucleated RBCs. Engineered RBCs expressing CD4 and CCR5 were efficiently infected by HIV-1, but CD4 or CD4-GpA expression in the absence of CCR5 was sufficient to potently neutralize HIV-1 in vitro. To facilitate continuous large-scale production of engineered RBCs, we generated erythroblast cell lines stably expressing CD4-GpA or ACE2-GpA fusion proteins, which produced potent RBC viral traps against HIV-1 and SARS-CoV-2. Our results suggest that this approach warrants further investigation as a potential treatment against viral infections.

Sign in / Sign up

Export Citation Format

Share Document